← All trials
NCT03220477
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 4, 2017
- Primary completion
- Jul 31, 2020
- Completion date
- Jul 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 57
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Memorial Sloan-Kettering Cancer CenterLead sponsor
- MerckCollaborator
- Astex Pharmaceuticals, Inc.Collaborator
- Memorial Sloan-Kettering Cancer CenterOverall official - principal investigator
- Stand Up To CancerCollaborator
- Mirati Therapeutics Inc.Collaborator
- Van Andel Research InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.